When NeoTherapeutics Inc. 's lead candidate leteprinim potassium (Neotrofin) failed in late stage trials for Alzheimer's earlier this year, the cash-strapped company was forced to pawn a remaining asset—just as many other biotechs are having to do. (See "Germany's Biotech Bust," this issue, Also see "Germany's Biotech Bust" - In Vivo, 1 November, 2002..) Unable to afford to take its Phase II cancer compound satraplatin through the rest of clinical development, NeoTherapeutics had to bring in a partner.
GPC Biotech AG was perfectly positioned to snap up this rare thing, a late-stage development compound. With $127 million...


